Epicure Therapeutics, Inc.

EpiCure Therapeutics is building circuit selective adeno-associated virus (AAV) gene therapies and optimized expression systems to
cure epilepsies, with an initial focus on Dravet syndrome. The venture uses its vectors to only target the brain circuit involved in the disease pathogenesis, enabling more precise and effective treatment. The delivery of full SCN1A gene supplementation offers enhanced efficacy and safety, particularly for patients with missense mutations, compared to competitors' upregulation approaches.